Skip to main content
Premium Trial:

Request an Annual Quote

PositiveID, Receptors Co-Developing Test for Salmonella

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – PositiveID and its development partner Receptors today said they will be developing a product for the detection of Salmonella.

The product will be based on Receptors' Combinatorial Artificial Receptor Array, or CARA, technology, which PositiveID said could result in a faster, more efficient sample preparation process. The product may also be extended to other food-borne illnesses, such as E. coli, PositiveID said in a statement.

The CARA technology is based on a limited set of small-molecule building blocks, which are combined to created an array of "receptor environments," according to Receptors' website. The building blocks are covalently immobilized to a support surface, which results "in the reproducible display of all region-, stereo-, and spatial relationships possible for each combination of building blocks without the need for discrete synthesis," the firm said.

The announcement comes as an Iowa company last week issued a recall of about 380 million eggs due to possible Salmonella contamination.

PositiveID, based in Delray Beach, Fla., and Receptors, headquartered in Chaska, Minn., are currently co-developing an in vivo glucose-sensing microchip for diabetes and a point-of-care device for the rapid detection of influenza and other pandemic viruses.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more